MREO

Investigation Announcement

• Investigation by Pomerantz LLP: Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Mereo BioPharma Group plc and its officers or directors. Investors are encouraged to reach out for more information.

Recent Developments

• Orbit Study Update: On July 9, 2025, Mereo and Ultragenyx Pharmaceutical announced progress in the Phase 3 Orbit study for UX143 (setrusumab) aimed at treating osteogenesis imperfecta in pediatric and young adult patients. A final analysis is expected by the end of the year.

• Stock Price Reaction: Following the announcement, Mereo's American Depositary Receipt (ADR) price dropped significantly, falling by $1.25 per share, which is a 42.52% decrease, closing at $1.69 per share on July 10, 2025.

Pomerantz Firm Background

• Firm's Reputation: Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of over 80 years in fighting for victims of securities fraud and corporate misconduct. The firm has successfully recovered multimillion-dollar damages for class members in the past.

• Contact Information: Investors seeking more information can contact Danielle Peyton at Pomerantz LLP via email or phone.

• Investigation Announcement: Pomerantz LLP is investigating potential securities fraud or unlawful practices by Mereo BioPharma Group plc and its officers/directors, urging affected investors to contact them.

• Recent Developments: On July 9, 2025, Mereo and Ultragenyx Pharmaceutical announced progress in a Phase 3 study for UX143 (setrusumab) with a final analysis expected by year-end.

• Stock Price Impact: Following the announcement of the study's progress, Mereo's ADR price dropped significantly by 42.52%, closing at $1.69 per share on July 10, 2025.

• Pomerantz Firm Background: The Pomerantz Firm, established over 80 years ago, specializes in corporate, securities, and antitrust class litigation, advocating for victims of securities fraud and corporate misconduct.